Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Mar 24, 2014 1:18pm
126 Views
Post# 22359758

RE:RE:RE:RE:RVX - Managing Perceptions

RE:RE:RE:RE:RVX - Managing PerceptionsHi G1945V. Thanks for the helpful perspective.

Regarding the size of the float from what I recall there were 80MM shares of which about 66MM being traded. So I'll guess that insiders own 36MM (this is purely a guess). That leaves 30MM shares to be traded.

Now, if they split the shares 10 to 1 a few things could happen:
  1. There would now be 300MM shares in the trading pool.
  2. Insiders still retain their control and % of the shares.
  3. The share price could drop to the $0.07 to $0.10 range.
  4. This would open up share purchases to various groups including those that play even more toward the penny stock investors.
  5. Institutional investors could come to play as part of the high risk aspect of their portfolios.
  6. This extra demand could drive the share price up.
  7. It would enhance liquidity for investors like me.
  8. It could drive the stock profile higher.

Just a crazy thought.
Cheers
Toinv

Bullboard Posts